# SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

> **NCT04563520** · PHASE3 · RECRUITING · sponsor: **Emory University** · enrollment: 5 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Emicizumab
- **DRUG:** FEIBA
- **DRUG:** rFVIIa

## Key facts

- **NCT ID:** NCT04563520
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563520, "SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04563520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*